{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T17:06:45Z","timestamp":1787677605031,"version":"build-2784847793"},"reference-count":26,"publisher":"Public Library of Science (PLoS)","issue":"12","license":[{"start":{"date-parts":[[2013,12,30]],"date-time":"2013-12-30T00:00:00Z","timestamp":1388361600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0083026","type":"journal-article","created":{"date-parts":[[2013,12,30]],"date-time":"2013-12-30T21:18:14Z","timestamp":1388438294000},"page":"e83026","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":75,"title":["Natural History of Malignant Bone Disease in Renal Cancer: Final Results of an Italian Bone Metastasis Survey"],"prefix":"10.1371","volume":"8","author":[{"given":"Daniele","family":"Santini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Procopio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camillo","family":"Porta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toni","family":"Ibrahim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandro","family":"Barni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Calogero","family":"Mazzara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Fontana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfredo","family":"Berruti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rossana","family":"Berardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Vincenzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cinzia","family":"Ortega","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Ottaviani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giacomo","family":"Carteni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaetano","family":"Lanzetta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vladimir","family":"Virz\u00ec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Santoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Silvestris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Antonietta","family":"Satolli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Collov\u00e0","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Russo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Badalamenti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano Luzi","family":"Fedeli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca Maria","family":"Tanca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Adamo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evaristo","family":"Maiello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Sabbatini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Felici","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saverio","family":"Cinieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Tonini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio","family":"Bracarda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2013,12,30]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/j.eururo.2011.06.049","article-title":"The epidemiology of renal cell carcinoma","volume":"60","author":"B Ljungberg","year":"2011","journal-title":"Eur Urol"},{"key":"ref2","first-page":"3954","article-title":"Treatment options for metastatic renal cell carcinoma: a review","volume":"15","author":"U Athar","year":"2008","journal-title":"Can J Urol"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1056\/NEJM199609193351207","article-title":"Renal-cell carcinoma","volume":"335","author":"RJ Motzer","year":"1996","journal-title":"N Engl J Med"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"2637","DOI":"10.1002\/cncr.25750","article-title":"Progression-free survival as a predictor of overall survival in metastatic renal cell carcinoma treated with contemporary targeted therapy","volume":"117","author":"DY Heng","year":"2011","journal-title":"Cancer"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1002\/1097-0142(20010815)92:4<761::AID-CNCR1380>3.0.CO;2-#","article-title":"Feasibility of prolonged use of interferon-alpha in metastatic kidney carcinoma: a phase II study","volume":"92","author":"M Kankuri","year":"2001","journal-title":"Cancer"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.bone.2010.09.008","article-title":"Skeletal complications and survival in renal cancer patients with bone metastases","volume":"48","author":"E Woodward","year":"2011","journal-title":"Bone"},{"key":"ref7","first-page":"379","article-title":"The skeletal metastatic complications of renal cell carcinoma","volume":"19","author":"J Zekri","year":"2001","journal-title":"Int J Oncol"},{"issue":"Suppl. 2","key":"ref8","doi-asserted-by":"crossref","first-page":"S28","DOI":"10.1016\/j.ejon.2007.07.002","article-title":"Burden of bone disease","volume":"11","author":"N Kinnane","year":"2007","journal-title":"Eur J Oncol Nurs"},{"issue":"Suppl. 3","key":"ref9","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.ctrv.2005.09.004","article-title":"Zoledronic acid to prevent skeletal complications in cancer: corroborating the evidence","volume":"31","author":"MR Smith","year":"2005","journal-title":"Cancer Treat Rev"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s12253-009-9184-7","article-title":"Prognostic factors and survival of renal clear cell carcinoma patients with bone metastases","volume":"16","author":"A Szendroi","year":"2010","journal-title":"Pathol Oncol Res"},{"issue":"Suppl. 1","key":"ref11","doi-asserted-by":"crossref","first-page":"S38","DOI":"10.1053\/j.seminoncol.2010.06.001","article-title":"Zoledronic acid use in patients with bone metastases from renal cell carcinoma or bladder cancer","volume":"37","author":"F Saad","year":"2010","journal-title":"Semin Oncol"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"Brown JE, Lipton A, Cook RJ, Michaelson D, Coleman RE, <etal>et al<\/etal>. (2009) Correlation of N-telopeptide of type I collagen (NTX) and survival and fractures in patients (pts) with bone metastases from renal cell carcinoma (RCC). In ASCO 2009 Genitourinary Cancers Symposium (Abstract 342), Orlando, FL, 2009.","DOI":"10.1200\/jco.2009.27.15_suppl.e16016"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1002\/cncr.11571","article-title":"Zoledronic acid delays the onset of skeletal-related events and progression of skeletal disease in patients with advanced renal cell carcinoma","volume":"98","author":"A Lipton","year":"2003","journal-title":"Cancer"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1186\/1471-2407-9-272","article-title":"Natural history of malignant bone disease in breast cancer and the use of cumulative mean functions to measure skeletal morbidity","volume":"9","author":"PP Major","year":"2009","journal-title":"BMC Cancer"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"61","DOI":"10.2214\/ajr.129.1.61","article-title":"Radiographic manifestations of bone metastases from renal carcinoma","volume":"129","author":"GS Forbes","year":"1977","journal-title":"AJR Am J Roentgenol"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"6397S","DOI":"10.1158\/1078-0432.CCR-040030","article-title":"Skeletal complications in patients with bone metastases from renal cell carcinoma and therapeutic benefits of zoledronic acid","volume":"10","author":"A Lipton","year":"2004","journal-title":"Clin Cancer Res"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/j.ejca.2012.02.050","article-title":"Bisphosphonates combined with sunitinib may improve the response rate, progression free survival and overall survival of patients with bone metastases from renal cell carcinoma","volume":"48","author":"D Keizman","year":"2012","journal-title":"Eur J Cancer"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1111\/j.1464-410X.2009.08987.x","article-title":"Vascular endothelial growth factor and mTOR pathways in renal cell carcinoma: differences and synergies of two targeted mechanisms","volume":"104","author":"P Mulders","year":"2009","journal-title":"BJU Int"},{"issue":"Suppl. 2","key":"ref19","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1634\/theoncologist.2011-S2-14","article-title":"Targeted therapies for the treatment of metastatic renal cell carcinoma: clinical evidence","volume":"16","author":"TE Hutson","year":"2011","journal-title":"Oncologist"},{"key":"ref20","unstructured":"European Medicines Agency. Votrient (Pazopanib) Authorisation Details; <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/medicines\/human\/medicines\/001141\/human_med_001337.jsp&murl=menus\/medicines\/medicines.jsp&mid=WC0b01ac058001d124&jsenabled=true\" xlink:type=\"simple\">http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/medicines\/human\/medicines\/001141\/human_med_001337.jsp&amp;murl=menus\/medicines\/medicines.jsp&amp;mid=WC0b01ac058001d124&amp;jsenabled=true<\/ext-link> (11 December 2012, date last accessed)."},{"key":"ref21","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1200\/JCO.2001.19.2.558","article-title":"Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials","volume":"19","author":"P Major","year":"2001","journal-title":"J Clin Oncol"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1056\/NEJM199612123352401","article-title":"Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group","volume":"335","author":"GN Hortobagyi","year":"1996","journal-title":"N Engl J Med"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1056\/NEJM199602223340802","article-title":"Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group","volume":"334","author":"JR Berenson","year":"1996","journal-title":"N Engl J Med"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"3150","DOI":"10.1200\/JCO.2003.04.105","article-title":"Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial\u2014the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group","volume":"21","author":"LS Rosen","year":"2003","journal-title":"J Clin Oncol"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1200\/JCO.2010.31.3304","article-title":"Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma","volume":"29","author":"DH Henry","year":"2011","journal-title":"J Clin Oncol"},{"issue":"Suppl. 1","key":"ref26","doi-asserted-by":"crossref","first-page":"S66","DOI":"10.1053\/j.seminoncol.2010.06.006","article-title":"Safety considerations for use of bone-targeted agents in patients with cancer","volume":"37","author":"JE Mortimer","year":"2010","journal-title":"Semin Oncol"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0083026","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,21]],"date-time":"2022-03-21T02:13:59Z","timestamp":1647828839000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0083026"}},"subtitle":[],"editor":[{"given":"Bart O.","family":"Williams","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2013,12,30]]},"references-count":26,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2013,12,30]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0083026","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,12,30]]}}}